Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) — Stock Score Summary

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) has a MoatMap StockRank of 28/100 based on Quality (66/100), Value (14/100), and Momentum (36/100) factor scores. The current signal is SELL. While Zelgen is a biopharmaceutical firm with a decent quality score, it is a drug developer rather than a CDMO, meaning it does not benefit from the CDMO pricing power cycle and instead faces high R&D risks.

Suzhou Zelgen Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule drugs and biologics for oncology and liver diseases. The company's competitive moat is anchored by its proprietary drug discovery platforms, including its precision small-molecule and complex recombinant protein technologies. It is a prominent biotechnology innovator with a robust pipeline of first-in-class and best-in-class therapies.

Key Financial Metrics

Price$13.51
Market Cap$3.9B
P/E (TTM)48.38
P/E (Forward)-1299.43
Price/Book14.06
Return on Equity33.8%
Return on Invested Capital-9.4%
Debt/Equity57.53
Gross Margin94.2%
Operating Margin69.6%
Revenue Growth440.1%
Free Cash Flow$1M

Suzhou Zelgen Biopharmaceuticals Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Suzhou Zelgen Biopharmaceuticals Co., Ltd.’s (688266.SS) StockRank?
MoatMap’s StockRank for Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) is 28/100, with a Sell signal. It is a composite of Quality (66), Value (14), and Momentum (36) factor ranks across MoatMap’s 19,000+ stock universe.
Does Suzhou Zelgen Biopharmaceuticals Co., Ltd. have an economic moat?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Suzhou Zelgen Biopharmaceuticals Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Suzhou Zelgen Biopharmaceuticals Co., Ltd. in?
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688266.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock